Cargando…
Non-alcoholic fatty liver disease and liver secretome
Metabolism of carbohydrates and lipids and protein degradation occurs in the liver and contributes to the body's homeostasis by secreting a variety of mediators. Any imbalance in this homeostasis due to excess fat consumption and the pathologic events accompanying lipotoxicity, autophagy dysreg...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pharmaceutical Society of Korea
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703441/ https://www.ncbi.nlm.nih.gov/pubmed/36441472 http://dx.doi.org/10.1007/s12272-022-01419-w |
_version_ | 1784839849470066688 |
---|---|
author | Khan, Muhammad Sohaib Lee, Choongho Kim, Sang Geon |
author_facet | Khan, Muhammad Sohaib Lee, Choongho Kim, Sang Geon |
author_sort | Khan, Muhammad Sohaib |
collection | PubMed |
description | Metabolism of carbohydrates and lipids and protein degradation occurs in the liver and contributes to the body's homeostasis by secreting a variety of mediators. Any imbalance in this homeostasis due to excess fat consumption and the pathologic events accompanying lipotoxicity, autophagy dysregulation, endoplasmic reticulum stress, and insulin resistance may cause disturbances in the secretion of the proteins from the liver and their physiologic modifications and interactions with others. Since the liver secretome plays a role in the regulation of fuel metabolism and inflammation not only in the liver per se but also in other organs, the proteins belong to the utmost targets for treating metabolic and inflammatory diseases (e.g., COVID-19), depending on the available and feasible approaches to controlling their biological effects. However, in this era, we still come across new liver-derived proteins but are yet unable to entirely understand the pathologic basis underlying disease progression. This review aims to provide an updated overview of liver secretome biology with explanatory mechanisms with regard to the progression of metabolic and inflammatory liver diseases. |
format | Online Article Text |
id | pubmed-9703441 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Pharmaceutical Society of Korea |
record_format | MEDLINE/PubMed |
spelling | pubmed-97034412022-11-28 Non-alcoholic fatty liver disease and liver secretome Khan, Muhammad Sohaib Lee, Choongho Kim, Sang Geon Arch Pharm Res Review Metabolism of carbohydrates and lipids and protein degradation occurs in the liver and contributes to the body's homeostasis by secreting a variety of mediators. Any imbalance in this homeostasis due to excess fat consumption and the pathologic events accompanying lipotoxicity, autophagy dysregulation, endoplasmic reticulum stress, and insulin resistance may cause disturbances in the secretion of the proteins from the liver and their physiologic modifications and interactions with others. Since the liver secretome plays a role in the regulation of fuel metabolism and inflammation not only in the liver per se but also in other organs, the proteins belong to the utmost targets for treating metabolic and inflammatory diseases (e.g., COVID-19), depending on the available and feasible approaches to controlling their biological effects. However, in this era, we still come across new liver-derived proteins but are yet unable to entirely understand the pathologic basis underlying disease progression. This review aims to provide an updated overview of liver secretome biology with explanatory mechanisms with regard to the progression of metabolic and inflammatory liver diseases. Pharmaceutical Society of Korea 2022-11-28 2022 /pmc/articles/PMC9703441/ /pubmed/36441472 http://dx.doi.org/10.1007/s12272-022-01419-w Text en © The Pharmaceutical Society of Korea 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Khan, Muhammad Sohaib Lee, Choongho Kim, Sang Geon Non-alcoholic fatty liver disease and liver secretome |
title | Non-alcoholic fatty liver disease and liver secretome |
title_full | Non-alcoholic fatty liver disease and liver secretome |
title_fullStr | Non-alcoholic fatty liver disease and liver secretome |
title_full_unstemmed | Non-alcoholic fatty liver disease and liver secretome |
title_short | Non-alcoholic fatty liver disease and liver secretome |
title_sort | non-alcoholic fatty liver disease and liver secretome |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703441/ https://www.ncbi.nlm.nih.gov/pubmed/36441472 http://dx.doi.org/10.1007/s12272-022-01419-w |
work_keys_str_mv | AT khanmuhammadsohaib nonalcoholicfattyliverdiseaseandliversecretome AT leechoongho nonalcoholicfattyliverdiseaseandliversecretome AT kimsanggeon nonalcoholicfattyliverdiseaseandliversecretome |